UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative therapy does not exist or is no longer effective
• •* Gastrointestinal, lung, and ovarian malignancies are given priority
• •No brain metastases
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2 OR
• •Karnofsky 60-100%
• •Life expectancy
• •More than 3 months
• •Hematopoietic
• •WBC at least 3,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic
• •Bilirubin normal
• •AST/ALT no greater than 2.5 times upper limit of normal (ULN)
• •Renal
• •Creatinine normal OR
• •Creatinine clearance at least 60 mL/min
• •Cardiovascular
• •No symptomatic coronary artery disease
• •No symptomatic cardiac dysfunction
• •No symptoms suggestive of coronary artery disease
• •LVEF at least 50%
• •Pulmonary
• •No symptomatic pulmonary dysfunction
• •FEV\_1 greater than 75% of predicted
• •DLCO greater than 75% of predicted
• •Other
• •Amylase no greater than 2 times ULN
• •No other concurrent uncontrolled illness
• •No ongoing or active infection
• •No psychiatric illness or social situation that would preclude study compliance
• •No diabetes mellitus or random glucose more than 200 mg/dL
• •No prior allergic reaction attributed to compounds of similar biological or chemical composition to UCN-01 or irinotecan (including rash and systemic allergic reaction causing hypotension and respiratory distress)
• •No chronic diarrhea (more than 5 stools/day)
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception for 14 days before, during, and for at least 30 days after study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• •Prior UCN-01 and irinotecan allowed
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •At least 4 weeks since prior radiotherapy and recovered
• •No prior mediastinal radiation
• •Surgery
• •Not specified
• •Other
• •At least 14 days since prior warfarin
• •No concurrent warfarin unless required for maintaining patency of existing, permanent IV catheters
• •No concurrent commercial or other investigational anticancer agents or therapies
• •No concurrent combination antiretroviral therapy for HIV-positive patients